This year, Nord Hydrogen was invited to attend the International H2 Conference in Tokyo — one of the most significant gatherings in molecular hydrogen research. It was three days that reminded us exactly why we do what we do.
Japan is not a random location for a conference like this. It was here, in 2007, that researchers at Nippon Medical School published the landmark paper in Nature Medicine that put molecular hydrogen on the scientific map. Since then, more than 2,000 studies have followed. Tokyo has been the epicenter of this field for nearly two decades — and the conference reflected that history.
The room was unlike anything we expected
When you build a product grounded in science, you spend a lot of time alone with research papers. What the conference gave us was something different: the people behind those papers, in the same room, talking to each other — and to us.
Doctors. PhD researchers. Leading institutions from Japan, Europe, and the United States. Companies pushing the technology forward. The conversations were direct, detailed, and at times genuinely surprising in how aligned the consensus has become.
"The science is no longer fringe. The question being asked in Tokyo was not whether hydrogen works — it was how to scale the delivery and get it into the hands of more people."
What we took away
Three things stood out clearly from the sessions and conversations.
First: the evidence base has grown faster in the last three years than the previous decade combined. The 2024 meta-analyses on fatigue, inflammation, and metabolic health were cited repeatedly — not as curiosities, but as the foundation for the next wave of clinical work.
Second: delivery still matters more than most people realise. The consensus among researchers was firm — concentration and freshness at the point of consumption determine whether hydrogen actually reaches the cells that need it. This is not a detail. It is the whole game.
Third: the field is moving from research to application. The scientists we met are no longer asking whether hydrogen has therapeutic potential. They are working on specific protocols, specific populations, and specific delivery systems. The clinical infrastructure is being built now.
Why this matters for Nord Hydrogen
We did not go to Tokyo to validate what we already believed. We went to be challenged. What we found instead was a scientific community that has quietly arrived at many of the same conclusions we built our product around — and is pushing further in the direction we are already heading.
Being in that room, as an invited participant, confirmed something important: Nord Hydrogen is not a wellness trend. It is a product built on a rapidly maturing body of science, designed to deliver what the research actually demands.
We came home with new contacts, new research to dig into, and a clearer sense of what comes next